Advertisement

Geriatric Oncology

Efficacy of Risk Calculator in Treating Elderly Patients With Cancer

Researchers have shown that using a validated risk calculator helped to drive informed treatment decisions in older patients with cancer. Mbewe et al identified the Cancer and Aging Research Group (CARG) calculator as a quick and helpful tool in assessing chemotherapy toxicity probability in...

Multiple Myeloma
Immunotherapy

CASSIOPEIA Part 2: Maintenance Daratumumab After Initial Therapy for Newly Diagnosed Multiple Myeloma

As reported in The Lancet Oncology by Philippe Moreau, MD, and colleagues, an interim analysis of part 2 of the phase III CASSIOPEIA trial has shown significantly prolonged progression-free survival with maintenance daratumumab vs observation following induction and consolidation with or without...

Colorectal Cancer

Hepatectomy With or Without Adjuvant mFOLFOX6 for Liver-Only Metastatic Colorectal Cancer: Disease-Free and Overall Survival

In the Japanese phase II/III JCOG0603 trial reported in the Journal of Clinical Oncology, Kanemitsu et al found that the addition of adjuvant mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin) to hepatectomy improved disease-free survival in patients with liver-only metastatic colorectal cancer;...

Lung Cancer

Classifying EGFR Mutations by Structure and Function May Help to Match Patients With NSCLC to More Effective Treatments

Researchers have discovered that grouping EGFR mutations by structure and function provides an accurate framework to match patients with non–small cell lung cancer (NSCLC) to the right drugs. The findings, published by Robichaux et al in Nature, identify four subgroups of mutations and introduce a...

Issues in Oncology

Study Shows Benefits of a Next-Day Access Program for Patients With Cancer

A pilot program developed by researchers at Yale Cancer Center that offers patients next-day access for oncologic consultation showed reduced wait times for initial access to cancer care and increased patient satisfaction, according to a new report presented by Mougalian et al at the 2021 ASCO...

Skin Cancer

Overall Survival With the Bispecific Fusion Protein Tebentafusp for Metastatic Uveal Melanoma

In an interim analysis of the phase III IMCgp100-202 trial reported in The New England Journal of Medicine, Nathan et al found that tebentafusp, a bispecific protein consisting of an affinity-enhanced T-cell receptor fused to an anti-CD3 effector, significantly improved overall survival vs...

Hepatobiliary Cancer
Issues in Oncology

Are Rates of Hepatocellular Carcinoma Rising in Rural Areas of the United States?

Historically, rates of hepatocellular carcinoma (HCC) have been lower in rural areas than urban regions. However, a recent study published by Zhou et al in Clinical Gastroenterology and Hepatology shows that while cases of HCC have begun slowing in urban communities in the United States, the...

Breast Cancer
Survivorship

Active Living After Cancer Program May Improve Physical Functioning for Breast Cancer Survivors

Breast cancer survivors who participated in Active Living After Cancer, an evidence-based 12-week group program, markedly increased their physical activity and ability to accomplish the basic pursuits of daily life, reported Tami-Maury et al in the journal Cancer. The results show the program could ...

Issues in Oncology

New Study Aims to Measure Success of Phase III Oncology Trials

New research published by Shen et al in JNCCN—Journal of the National Comprehensive Cancer Network has found that more than 80% of therapies tested in phase III oncology trials did not achieve meaningful clinical benefit in prolonging survival.

The researchers analyzed 362 industry-sponsored phase...

Pancreatic Cancer
Genomics/Genetics

Risk of Pancreatic Cancer Associated With Germline ATM Pathogenic Variants

In a multicenter cohort study reported in JAMA Oncology, Hsu et al found that among pancreatic cancer kindreds, individuals with germline ATM pathogenic variants had a sixfold increased risk of developing pancreatic cancer vs noncarriers of pathogenic variants.

Study Details

The study involved data ...

Lung Cancer

Overall Survival With Stereotactic Ablative Radiotherapy for Operable Stage IA NSCLC

As reported in The Lancet Oncology by Chang et al, long-term results of the single-institution revised STARS trial indicate that overall survival in patients receiving stereotactic ablative radiotherapy (SABR) for operable stage IA non–small cell lung cancer (NSCLC) was noninferior to that in a...

Colorectal Cancer

Capecitabine Maintenance After First-Line Therapy for Metastatic Colorectal Cancer

In the FOCUS4-N trial reported in the Journal of Clinical Oncology, Adams et al found that capecitabine maintenance improved progression-free—but not overall—survival vs active monitoring in patients with stable disease or objective response after first-line therapy for metastatic colorectal...

Breast Cancer
Immunotherapy

DESTINY Breast03: Second-Line Fam-Trastuzumab Deruxtecan-nxki for Metastatic HER2-Positive Breast Cancer

Fam-trastuzumab deruxtecan-nxki (T-DXd) showed statistically significant improvement in progression-free survival vs trastuzumab emtansine (T-DM1) in second-line treatment for HER2-positive unresectable or metastatic breast cancer, according to results from the global phase III DESTINY-Breast03...

Lung Cancer
COVID-19

Almost Two-Thirds of Surveyed Thoracic Oncologists Reported Using Telehealth for the First Time During the COVID-19 Pandemic

Nearly two-thirds of thoracic oncologists surveyed indicated they used telehealth tools for the first time during the COVID-19 pandemic, according to a report issued by Baird et al at the International Association for the Study of Lung Cancer (IASLC) 2021 World Conference on Lung Cancer (Abstract...

Lung Cancer
Immunotherapy

DESTINY-Lung01: Fam-trastuzumab Deruxtecan-nxki in Previously Treated HER2-Mutant NSCLC

In the phase II DESTINY-Lung01 trial, presented at the European Society for Medical Oncology (ESMO) Congress 2021 (Abstract LBA45) and concurrently reported in The New England Journal of Medicine, Bob T. Li, MD, PhD, MPH, and colleagues found that fam-trastuzumab deruxtecan-nxki produced durable...

COVID-19

FDA Authorizes Booster Dose of Pfizer-BioNTech COVID-19 Vaccine for Certain Populations

The U.S. Food and Drug Administration (FDA) has amended the emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 vaccine to allow for the use of a single booster dose to be administered at least 6 months after completion of the primary series in individuals aged 65 years and older;...

Lung Cancer
Immunotherapy

Neoadjuvant Atezolizumab Under Study for Resectable Pleural Mesothelioma

Neoadjuvant atezolizumab combined with pemetrexed and cisplatin, followed by surgical resection and maintenance atezolizumab, proved safe and feasible and offered hints of benefit in patients with resectable pleural mesothelioma. Results from a small multicenter study were presented by Boris...

Lung Cancer
Immunotherapy

Maintenance Durvalumab: Increased Utilization Could Improve NSCLC Outcomes

Maintenance durvalumab—the recommended maintenance treatment for patients with unresectable stage III non–small cell lung cancer (NSCLC) following chemoradiation—remains significantly underutilized, according to research presented by Liu et al at the International Association for the Study of Lung...

Lung Cancer
Immunotherapy

Atezolizumab Plus Chemotherapy in Patients With Advanced NSCLC and Brain Metastases

Patients with advanced non–small cell lung cancer (NSCLC) and brain metastases derived benefit from treatment with atezolizumab plus chemotherapy, according to findings from the multicenter phase II ATEZO-BRAIN/GECP 17/05 trial. The study was presented at the International Association for the Study ...

Lung Cancer
Immunotherapy

IMpower010 Study of Atezolizumab in Resectable NSCLC: Benefits Observed Regardless of Stage, Type of Prior Treatment

In an exploratory analysis of the pivotal phase III IMpower010 trial—which found that adjuvant atezolizumab significantly improved disease-free survival in resectable non–small cell lung cancer (NSCLC)—benefit was shown regardless of the type of surgery or the chemotherapy doublet received by the...

Neuroendocrine Tumors

Study Examines Efficacy of Sunitinib in Malignant Pheochromocytoma and Paraganglioma

The first randomized study in patients with malignant pheochromocytoma and paraganglioma has found that sunitinib prolongs progression-free survival by more than 5 months. The late-breaking results of the FIRSTMAPPP trial were presented by Eric Baudin, MD, PhD, and colleagues at the European...

Prostate Cancer

PEACE-1 and STAMPEDE Trials: Abiraterone Acetate Plus Prednisolone in Prostate Cancer

A novel combination of well-known drugs may prolong survival in patients with prostate cancer, according to late-breaking research presented at the European Society for Medical Oncology (ESMO) Congress 2021. The PEACE-1 and STAMPEDE studies found that the addition of abiraterone acetate plus...

Multiple Myeloma

Consolidation Treatment With VRD Followed by Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma

In a phase III European Myeloma Network trial (EMN02/HOVON95) reported in the Journal of Clinical Oncology, Sonneveld et al found that consolidation with bortezomib, lenalidomide, and dexamethasone (VRD) vs no consolidation followed by maintenance lenalidomide was associated with significantly...

Gynecologic Cancers

Does Adjuvant Image-Guided Intensity-Modulated Radiotherapy for Cervical Cancer Lead to Increased Rates of Late Toxicity?

In the Indian single-center phase III PARCER trial reported in the Journal of Clinical Oncology, Supriya Chopra, MD, DNB, and colleagues found that adjuvant image-guided intensity-modulated radiotherapy (IG-IMRT) was associated with less late grade ≥ 2 gastrointestinal toxicity vs three-dimensional ...

Leukemia

First-Line Acalabrutinib, Venetoclax, and Obinutuzumab for Chronic Lymphocytic Leukemia

In a phase II study reported in The Lancet Oncology, Matthew S. Davids, MD, and colleagues found that first-line triple combination therapy with acalabrutinib, venetoclax, and obinutuzumab produced measurable residual disease (MRD)-negative complete remission in a substantial proportion of patients ...

Gynecologic Cancers
Immunotherapy

KEYNOTE-826: Pembrolizumab Plus Chemotherapy in Advanced Cervical Cancer

The addition of pembrolizumab to chemotherapy prolonged survival in recurrent, persistent, or metastatic cervical cancer, according to results of the KEYNOTE-826 study presented at the European Society for Medical Oncology (ESMO) Congress 2021 by Nicoletta Colombo, MD, and colleagues (Abstract...

Skin Cancer
Immunotherapy

Adjuvant Pembrolizumab for High-Risk Stage II Melanoma: Efficacy and Safety Examined

Adjuvant pembrolizumab reduced the risk of disease recurrence in adults and children aged 12 years and older with high-risk stage II melanoma vs placebo, according to a late-breaking interim analysis of the phase III KEYNOTE-716 trial presented by Jason J. Luke, MD, and colleagues at the European...

Breast Cancer

MONALEESA-2: Ribociclib Plus Endocrine Therapy Extends Overall Survival in Postmenopausal Patients With Metastatic Breast Cancer

Results from the phase III MONALEESA-2 trial showed a significant overall survival benefit with ribociclib plus endocrine therapy for postmenopausal patients with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer. This is the first demonstration of a survival advantage with a...

Gynecologic Cancers

Relacorilant Plus Nab-paclitaxel May Improve Progression-Free Survival in Recurrent Platinum-Resistant Ovarian Cancer

In the first randomized, controlled study to explore the efficacy and safety of relacorilant—a selective glucocorticoid receptor modulator—in combination with nab-paclitaxel compared to nab-paclitaxel alone, the combination improved progression-free survival and showed a favorable safety profile in ...

Lymphoma

FDA Grants Zanubrutinib Accelerated Approval in Relapsed or Refractory Marginal Zone Lymphoma

On September 15, zanubrutinib (Brukinsa), a small-molecule inhibitor of Bruton’s tyrosine kinase (BTK), received accelerated approval from the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory marginal zone lymphoma who have received at least...

Hematologic Malignancies
Symptom Management

Ruxolitinib Granted FDA Approval for Chronic Graft-vs-Host Disease

On September 22, the U.S. Food and Drug Administration approved ruxolitinib (Jakafi), a JAK inhibitor, for the treatment of chronic graft-vs-host disease (GVHD) after failure of one or two lines of systemic therapy in adult and pediatric patients aged 12 years and older.

REACH3

Efficacy was...

Bladder Cancer

DD-MVAC vs Gemcitabine/Cisplatin for Muscle-Invasive Bladder Cancer

The randomized phase III controlled GETUG/AFU VESPER V05 trial was designed to compare the efficacy of two perioperative treatment regimens—gemcitabine/cisplatin or dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (dd-MVAC)—in patients with muscle-invasive bladder cancer. The...

Lymphoma
Immunotherapy

Long-Term Outcomes in JULIET Trial of Tisagenlecleucel for Relapsed or Refractory Aggressive B-Cell Lymphomas

As reported by Stephen J. Schuster, MD, and colleagues in The Lancet Oncology, long-term outcomes of the pivotal phase II JULIET trial showed overall and complete response rates of 53% and 39% in adult patients with relapsed or refractory aggressive B-cell lymphomas treated with the T-cell...

Issues in Oncology

Single-Fraction vs Multifraction SABR for Pulmonary Oligometastases: Is There a Difference in Safety or Efficacy?

In the phase II SAFRON II study reported in JAMA Oncology, Shankar Siva, PhD, MBBS, FRANZCR, and colleagues found no significant differences in safety or efficacy between single-fraction vs multifraction stereotactic ablative body radiotherapy (SABR) for the treatment of pulmonary oligometastases.

...

Breast Cancer

Association of Pathologic Residual Cancer Burden and Event-Free Survival After Neoadjuvant Treatment for High-Risk Breast Cancer

In an analysis from the I-SPY2 trial reported in JAMA Oncology, W. Fraser Symmans, MD, and colleagues found that increasing residual cancer burden after neoadjuvant treatment for high-risk breast cancer was associated with poorer event-free survival.

Study Details

In I-SPY2, investigational agents...

Head and Neck Cancer
Geriatric Oncology

Role of Geriatric Assessment in Personalizing Therapy for Elderly Patients With Head and Neck Cancer

In a prospective evaluation of the role of comprehensive geriatric assessment in personalizing therapy for elderly patients with locally advanced head and neck squamous cell carcinoma (HNSCC), geriatric intervention changed therapeutic choices in about 1 out of 10 patients and played an important...

Kidney Cancer
Immunotherapy

COSMIC-021: Cabozantinib Plus Atezolizumab for Advanced Renal Cell Carcinoma

In the phase Ib COSMIC-021 trial reported in the Journal of Clinical Oncology, Sumanta K. Pal, MD, FASCO, and colleagues found that the combination of cabozantinib and atezolizumab produced durable responses in patients with advanced renal cell carcinoma (RCC).

Study Details

One hundred and two...

Lung Cancer
Immunotherapy

Addition of Ramucirumab to Gemcitabine in Second-Line Treatment of Malignant Pleural Mesothelioma

In the Italian phase II RAMES trial reported in The Lancet Oncology, Pinto et al found that the addition of ramucirumab to gemcitabine improved overall survival in the second-line treatment of malignant pleural mesothelioma.

As noted by the investigators, “There is a preclinical rationale for...

Gynecologic Cancers
Immunotherapy

FDA Grants Accelerated Approval to Tisotumab Vedotin-tftv for Recurrent or Metastatic Cervical Cancer

On September 20, the U.S. Food and Drug Administration (FDA) granted accelerated approval to tisotumab vedotin-tftv (Tivdak), a tissue factor–directed antibody and microtubule inhibitor conjugate, for adult patients with recurrent or metastatic cervical cancer who experienced disease progression on ...

Colorectal Cancer
COVID-19

COVID-19 Lockdown May Be Associated With Higher Tumor Burden in Newly Diagnosed Patients With Metastatic Colorectal Cancer

In a French study reported in JAMA Network Open, Thierry et al found that tumor burden assessed as plasma circulating tumor DNA (ctDNA) was significantly higher among patients with newly diagnosed metastatic colorectal cancer screened for a clinical trial after vs before the first COVID-19 lockdown ...

Hematologic Malignancies

Mortality Trends After Allogeneic Blood or Marrow Transplantation

In an analysis from a Blood or Marrow Transplant Survivor Study cohort reported in JAMA Oncology, Smita Bhatia, MD, MPH, and colleagues found that late mortality among patients undergoing allogeneic blood or marrow transplantation for hematologic malignancies has declined over the past 40 years,...

Issues in Oncology

Study Finds Prior Authorization May Be Associated With Delayed Receipt of Oral Anticancer Drugs

Dozens of oral chemotherapy drugs have been approved by the U.S. Food and Drug Administration over the past 2 decades and are now being prescribed in the treatment of many cancer types. However, most oral anticancer drug prescriptions require coordination between payers and providers, which can...

Issues in Oncology

Integrating Community-Based Interventions Into Cancer Care for Low-Income and Minority Patients May Improve Quality of Life, Reduce Care Disparities

It has been well documented that a confluence of many factors, including low-socioeconomic status, contribute to health disparities and worse outcomes in minority patients with cancer. Strategies that partnered community-based health workers with low-income and minority patients with cancer...

Thyroid Cancer

FDA Approves Cabozantinib for Patients With Previously Treated Radioactive Iodine–Refractory Differentiated Thyroid Cancer

On September 17, the U.S. Food and Drug Administration (FDA) approved cabozantinib (Cabometyx) for the treatment of adult and pediatric patients aged 12 years and older with locally advanced or metastatic differentiated thyroid cancer that has progressed following prior vascular endothelial growth...

Leukemia
Immunotherapy

Experimental Small-Molecule Inhibitor May Improve Responses to Cellular Therapies in Advanced CLL

Too many “exhausted” T cells left in the wake of aggressive chemotherapy regimens for patients with advanced chronic lymphocytic leukemia (CLL) make it more challenging for chimeric antigen receptor (CAR) T-cell therapy to do its job. Now, a new study from researchers at the Perelman School of...

Leukemia
Immunotherapy

Donor-Derived CD7 CAR T Cells May Lead to Remissions in Patients With Relapsed or Refractory T-ALL

In a Chinese single-institution phase I study reported in the Journal of Clinical Oncology, Pan et al found that donor-derived CD7 chimeric antigen receptor (CAR) T-cell therapy produced a high complete remission rate in patients with relapsed or refractory T-cell acute lymphoblastic leukemia...

Leukemia
Genomics/Genetics

Effect of Concurrent Focal 22q11.22 Deletions and IKZF1 Alterations on Outcomes in Pediatric Patients With B-Cell ALL

In a study reported in JAMA Oncology, Mangum et al found that focal deletions in chromosome 22q11.22 were associated with poor outcomes in pediatric patients with B-cell acute lymphoblastic leukemia (ALL) with IKZF1 alterations.

As stated by the investigators, “Alterations in the IKZF1 gene drive...

Leukemia
Immunotherapy

AUTO1: CAR T-Cell Product for Adult Patients With Relapsed or Refractory B-Cell ALL

In a phase I trial (ALLCAR19) reported in the Journal of Clinical Oncology, Roddie et al found that the fast off-rate autologous CD19 chimeric antigen receptor (CAR) T-cell therapy CAT19-41BB-Z—also known as AUTO1—was well tolerated and produced high remission rates in adults with relapsed or...

COVID-19
Global Cancer Care

Estimated Impact of the COVID-19 Pandemic on Cancer Diagnosis and Survival in Chile Over the Next Decade

In a simulation-based study reported in The Lancet Oncology, Ward et al estimated that delay in diagnosis due to the COVID-19 pandemic in Chile will lead to an early surge of newly diagnosed cancers at later stages, resulting in excess mortality over the next 10 years.

As stated by the...

Lymphoma
Immunotherapy

Bispecific Antibody Epcoritamab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

In a phase I/II study reported in The Lancet, Hutchings et al found that the novel bispecific antibody epcoritamab produced high response rates in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Epcoritamab works by targeting CD3 and CD20 and inducing T-cell–mediated cytotoxic...

Colorectal Cancer

Association of Skeletal Muscle Area and Adiposity Measures With Inflammation and Outcomes in Nonmetastatic Colon Cancer

In a study reported in JAMA Network Open, Fleming et al found that low skeletal muscle area and high visceral-to-total fat ratio were associated with increased expression of proinflammatory cytokines and VEGF as well as worse 5-year outcomes in patients with nonmetastatic colon cancer.

Study...

Gastrointestinal Cancer
Immunotherapy
Gastroesophageal Cancer

DESTINY-Gastric02: Fam-Trastuzumab Deruxtecan-nxki Produces Responses in Patients With HER2-Positive Gastric Cancers

In the primary analysis of the phase II DESTINY-Gastric02 trial, fam-trastuzumab deruxtecan-nxki (T-DXd) produced clinically meaningful and durable responses in Western patients with advanced HER2-positive gastric or gastroesophageal junction cancers whose disease had progressed after a...

Solid Tumors

Long-Term Therapy With Bintrafusp Alfa in HPV-Associated Cancers

Bintrafusp alfa, a first-in-class bifunctional fusion protein composed of the extracellular domain of the TGF-βRII receptor fused to a human IgG1 monoclonal antibody blocking PD-L1, showed long-term efficacy and a manageable safety profile in patients with pretreated, immune checkpoint...

Solid Tumors
Genomics/Genetics

ATR Inhibitor Ceralasertib in ARID1A-Deficient and ARID1A-Intact Solid Tumors

In an ongoing phase II study, Aggarwal et al evaluated the efficacy of the ATR inhibitor ceralasertib alone and in combination with olaparib in patients with ARID1A-deficient and ARID1A-intact solid tumors. They observed antitumor activity with ceralasertib monotherapy in ARID1A-deficient solid...

Breast Cancer

Phase III Trial Investigates Extended Adjuvant Endocrine Therapy for Postmenopausal Patients With Breast Cancer

For patients with early-stage hormone receptor–positive breast cancer, extending the duration of letrozole after tamoxifen—for up to 8 years of total endocrine therapy—significantly improved invasive disease–free survival and overall survival over the standard treatment of approximately 5 years of...

COVID-19

Study Finds Up to 15% of Patients With Cancer Experience 'Long Haul' COVID-19

New details about patients with cancer who have been infected with COVID-19 have emerged from the large observational OnCOVID study. According to data presented by Alessio Cortellini, MD, and colleagues at the European Society for Medical Oncology (ESMO) Congress 2021 (Abstract 1560O_PR),...

Immunotherapy

Can Diabetes Affect the Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Cancer?

Investigators from 22 institutions aimed to evaluate the impact of diabetes mellitus in a retrospective cohort of patients with advanced cancer treated with a single-agent immune checkpoint inhibitor. In a report presented by Cortellini et al at the European Society for Medical Oncology (ESMO)...

Issues in Oncology
Supportive Care
Global Cancer Care

Study Examines How Children Cope With a Parent’s Cancer Diagnosis

A cancer diagnosis can abruptly and durably alter the course of daily life—not just for the person diagnosed but also for family members. New research presented by Sinen Korbi, MD, and colleagues at the European Society for Medical Oncology (ESMO) Congress 2021 examined the coping mechanisms of...

FDA Grants Accelerated Approval to Mobocertinib for Patients With Metastatic NSCLC and EGFR Exon 20 Insertion Mutations

On September 15, the U.S. Food and Drug Administration (FDA) granted accelerated approval to mobocertinib (Exkivity) for adults with locally advanced or metastatic non–small cell lung cancer (NSCLC) and EGFR exon 20 insertion mutations (as detected by an FDA-approved test) whose disease has...

Lung Cancer
Issues in Oncology
Genomics/Genetics

Survey Examines Oncology Clinician Perceptions of Biomarker Testing for Underserved Patients With Lung Cancer

Less than half of community oncologists surveyed indicated that they use biomarker testing to guide patient discussions compared with 73% of academic clinicians, according to a report by Boehmer et al presented at the International Association for the Study of Lung Cancer (IASLC) 2021 World...

Issues in Oncology

Inclusion of Women in Oncology Clinical Trials From 2000 to 2020

In a study reported in a research letter in JAMA Oncology, Jenei et al found that women with cancer have been underrepresented in global oncology drug trials over the past 20 years, with underrepresentation persisting through the present in multiple cancer types.   

Study Details

The study...

Gynecologic Cancers
Immunotherapy

Nivolumab vs Gemcitabine or Pegylated Liposomal Doxorubicin: What Regimen Improves Survival in Platinum-Resistant Ovarian Cancer?

In a Japanese phase III trial (NINJA) reported in the Journal of Clinical Oncology, Hamanishi et al found that nivolumab did not improve overall survival vs chemotherapy with either gemcitabine or pegylated liposomal doxorubicin in platinum-resistant epithelial ovarian cancer.

Study Details

In...

COVID-19

Rates of Adverse Reactions to the Moderna mRNA-1273 COVID-19 Vaccine in Patients With Cancer and Recent Radiotherapy

In an Italian single-center study reported in a letter in The Lancet Oncology, Scoccianti et al found that patients who underwent radiotherapy for cancer within the 6 months prior to receipt of the Moderna mRNA-1273 COVID-19 vaccine did not experience a difference in adverse reactions to the...

Prostate Cancer

Racial Disparities Among Men With Prostate Cancer

Despite great strides in prostate cancer treatment over the past several years, racial disparities in care persist, according to new data presented during the 2021 Annual Meeting of the American Urological Association (AUA). Three studies highlighting this topic were presented during a virtual...

Bladder Cancer

Radical Cystectomy: Early-Stage Micropapillary Bladder Cancer Outcomes Similar to Late-Stage Conventional Urothelial Carcinoma

A study presented by Kevin Ginsburg, MD, and colleagues at the American Urological Association 2021 Annual Meeting has found that among patients treated with radical cystectomy, those with cT1 micropapillary bladder cancer had similar or worse oncologic outcomes compared with patients with cT2...

Prostate Cancer

Novel Urine-Based Test Evaluated in Prostate Cancer Detection and Risk Stratification

In a validation study with data presented at the American Urological Association’s 2021 Annual Meeting, clinician-researchers reported that a new test (miR Sentinel PCC4 Test) may be able to detect and risk-classify prostate cancer at the molecular level with predictive accuracy based on a single...

Issues in Oncology

Cancer-Specific Urgent Care Center: Effect on Emergency Department Use and Hospitalization Rate

In a single-institution study reported in JCO Oncology Practice, Gould Rothberg et al found that establishment of a dedicated cancer urgent care center within a large tertiary academic center resulted in a significant but modest decrease in emergency department use—but no significant reduction in...

Breast Cancer
Survivorship

Effect of Mindfulness Meditation and Survivorship Education on Depressive Symptoms in Younger Breast Cancer Survivors

In a phase III trial (Pathways to Wellness) reported in the Journal of Clinical Oncology, Julienne E. Bower, PhD, and colleagues found that both mindfulness meditation and survivorship education interventions significantly reduced depressive symptoms in younger breast cancer survivors.

Study...

Immunotherapy
Symptom Management

Technology-Enabled Monitoring of Adverse Reactions to Immune Checkpoint Inhibitors

In an interim analysis of a single-institution study reported in JAMA Network Open, Pavlos Msaouel, MD, PhD, and colleagues found that the use of a mobile device application for patient reporting of adverse reactions to immune checkpoint inhibition was feasible. It permitted identification of...

Lung Cancer

No Overall Survival Benefit With Lurbinectedin/Doxorubicin in Small Cell Lung Cancer

As a second-line treatment for patients with small cell lung cancer (SCLC), lurbinectedin plus doxorubicin failed to improve overall survival in the multicenter ATLANTIS trial, but it did provide other benefits, Luis Paz-Ares, MD, PhD, and colleagues reported at the International Association for...

Lung Cancer
Immunotherapy

POSEIDON Trial: Dual Checkpoint Blockade Plus Chemotherapy Improves Survival in First-Line Metastatic NSCLC

Findings from the phase III POSEIDON trial showed significantly improved progression-free and overall survival in patients with metastatic non–small cell lung cancer (NSCLC) who received first-line durvalumab and tremelimumab plus chemotherapy vs chemotherapy alone. These findings were presented by ...

Lung Cancer
Global Cancer Care

IASLC 2021: Study Examines Global Risk of Lung Cancer Due to Air Pollution

Five European countries rank highest for lung cancer risk attributable to air pollution among those aged 50 to 69 years, according to research presented by Berg et al in the Presidential Symposium Plenary Session at the International Association for the Study of Lung Cancer (IASLC) 2021 World...

Lung Cancer
COVID-19

IASLC 2021: Enrollment in Clinical Trials for Lung Cancer Declined Significantly During the COVID-19 Pandemic

Enrollment in lung cancer clinical trials declined by 43% during the COVID-19 pandemic, according to research presented by Smeltzer et al at the International Association for the Study of Lung Cancer (IASLC) 2021 World Conference on Lung Cancer (Abstract PL02.09).

IASLC Survey

To assess the...

Lung Cancer
COVID-19

IASLC 2021: Single-Center Study Examines Psychological Impact of the COVID-19 Pandemic on Patients With Lung Cancer

Patients coping with lung cancer treated at one hospital in Mexico reported high levels of anxiety and saw their treatment delayed due to the COVID-19 pandemic, according to a study presented by Oscar Arrieta, MD, at the 2021 International Association for the Study of Lung Cancer (IASLC) World...

COVID-19

Resurgence of COVID-19 Infection in a Large, Vaccinated Health System Workforce

In a letter to the editor in The New England Journal of Medicine, Keehner et al describe a marked resurgence of COVID-19 infections among fully vaccinated members of the University of California San Diego Health (UCSDH) workforce in July 2021. The resurgence appears to be driven by the confluence...

Gynecologic Cancers
Issues in Oncology

Study Finds Low-Poverty U.S. Counties May Eliminate Cervical Cancer 14 Years Earlier Than High-Poverty Counties

About 14,500 new cases of invasive cervical cancer are diagnosed each year in the United States and nearly 4,300 women die from the disease. Studies show that those living in higher-poverty areas experience higher rates of morbidity and mortality from many preventable cancers, including cervical...

Prostate Cancer

Effect of High-Intensity Interval Training on Biochemical Progression in Patients With Localized Prostate Cancer Under Active Surveillance

In a Canadian single-institution phase II study (ERASE) reported in JAMA Oncology, Kang et al found that increased exercise in the form of high-intensity interval training was associated with increased cardiorespiratory fitness and reductions in prostate-specific antigen (PSA) level, PSA velocity,...

Head and Neck Cancer
Issues in Oncology

HPV Vaccination and Projected Oropharyngeal Cancer Incidence Through the Year 2045

In a population-based age-period-cohort study reported in JAMA Oncology, Zhang et al estimated that current human papillomavirus (HPV) vaccination rates will have a limited impact on overall oropharyngeal cancer incidence through 2045, due to a high risk of oropharyngeal cancer in unvaccinated...

Lung Cancer
Genomics/Genetics

Genomic Analysis of Lung Cancer in Never-Smokers

A genomic analysis of lung cancer in people with no history of smoking has found that a majority of these tumors arise from the accumulation of mutations caused by natural processes in the body. This study was conducted by an international team led by researchers at the National Cancer Institute...

Immunotherapy
Geriatric Oncology

Biomarker Analysis Evaluates Potential for Immune Checkpoint Blockade Response in Older Patients With Cancer

A retrospective analysis of large data sets of biomarkers from tumors and healthy tissue by researchers at the Johns Hopkins Kimmel Cancer Center Convergence Institute suggests that older patients with cancer may benefit as much from cancer immunotherapies as younger patients. The findings,...

Cost of Care

Pharmacy Strategy to Decrease Patient Copayments for High-Cost Cancer Drugs Through Financial Assistance Applications

In an observational retrospective study reported in JCO Oncology Practice, Seymour et al describe a strategy used by Karmanos Specialty Pharmacy (KSP) to successfully decrease patient copayments for high-cost cancer drugs.

Study Details

The study involved data from the KSP claims data set,...

COVID-19

Rates of Newly Diagnosed Cancer Among U.S. Patients During the First Full Year of the COVID-19 Pandemic

In a study of Quest Diagnostics data reported as a research letter in JAMA Network Open, Kaufman et al found significant decreases in monthly new cancer diagnoses during the first full year of the COVID-19 pandemic compared with the prepandemic period.

As stated by the investigators, “We...

Lung Cancer
Immunotherapy

Several Studies Show Rovalpituzumab Tesirine Is Ineffective Against SCLC

Four independent studies published in the Journal of Thoracic Oncology demonstrate that rovalpituzumab tesirine (Rova-T), a first-in-class antibody-drug conjugate directed against delta-like protein 3 (DLL3), is not effective against small cell lung cancer (SCLC). An accompanying editorial by...

Lung Cancer

Ensartinib Shows Superior Efficacy to Crizotinib in Advanced ALK-Positive NSCLC: eXalt3 Trial

As reported in JAMA Oncology by Leora Horn, MD, MSc, FRCPC, and colleagues, the phase III eXalt3 trial has shown significantly prolonged progression-free survival with ensartinib vs crizotinib in patients with advanced, recurrent, or metastatic anaplastic lymphoma kinase (ALK)-positive non–small...

COVID-19

Teleoncology for Veterans With Cancer During the COVID-19 Pandemic

In a single-center study reported in JCO Oncology Practice, Jiang et al found an overall high level of satisfaction with teleoncology care during the COVID-19 pandemic among veterans with cancer in the United States, although a preference for in-person visits was commonly expressed. Teleoncology...

Skin Cancer
Immunotherapy

Phase II Trial Evaluates Oncolytic Coxsackievirus A21 for Unresectable Advanced Melanoma

In a phase II trial reported in the Journal of Clinical Oncology, Robert H.I. Andtbacka, MD, and colleagues found that intratumoral injection of the oncolytic RNA virus Coxsackievirus A21 (V937) was well tolerated and produced responses in some patients with unresectable stage III or stage IV...

Leukemia
Issues in Oncology

Ibrutinib and Cardiovascular Risk in Patients With Chronic Lymphocytic Leukemia

In a Canadian population-based cohort study reported in the Journal of Clinical Oncology, Abdel-Qadir et al found that ibrutinib treatment for chronic lymphocytic leukemia (CLL) is associated with increased risks of atrial fibrillation, bleeding, and heart failure, but not ischemic stroke or acute...

Solid Tumors
Genomics/Genetics

Cell-Free DNA Analysis to Distinguish Development of Malignant Peripheral Nerve Sheath Tumors From Plexiform Neurofibromas

The inherited condition neurofibromatosis type 1, or NF1, is responsible for the development of benign tumors that grow along the nerves; in some individuals, however, these benign tumors transform into aggressive and malignant peripheral nerve sheath tumors. Determining whether this transformation ...

Leukemia
Issues in Oncology

Study Suggests Demographic Enrollment Reporting Requirements for Acute Leukemia Clinical Trials Are Lacking

Requirements instituted to address racial and ethnic disparities in clinical trial enrollment did not lead to increased inclusion of Black and Hispanic participants in clinical acute leukemia research, according to a new study published by Andrew Hantel, MD, and colleagues in the journal Blood...

Bladder Cancer
Immunotherapy

Neoadjuvant Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab for Muscle-Invasive Bladder Cancer

In a phase II study reported in the Journal of Clinical Oncology, Tracy L. Rose, MD, MPH, and colleagues found that neoadjuvant therapy with pembrolizumab, gemcitabine, and primarily split-dose cisplatin resulted in pathologic downstaging (< pT2N0) in more than half of patients undergoing...

Breast Cancer

Addition of Everolimus to Letrozole in Premenopausal Women With Advanced HR-Positive, HER2-Negative Breast Cancer

In the Chinese phase II MIRACLE trial reported in JAMA Oncology, Fan et al found that the addition of everolimus to letrozole significantly improved progression-free survival among premenopausal women with advanced hormone receptor (HR)-positive, HER2-negative breast cancer whose disease had...

Skin Cancer
Immunotherapy

Pembrolizumab/Entinostat for Metastatic Uveal Melanoma

In the phase II PEMDAC study, researchers showed that the combination of the PD-1 inhibitor pembrolizumab and the histone deacetylase (HDAC) inhibitor entinostat resulted in durable responses in a small group of patients with metastatic uveal melanoma. These findings were published by Ny et al in

Breast Cancer

Early-Stage Research on Dual-Action Estrogen Receptor Inhibitors for Breast Cancer

A set of compounds developed by scientists at Scripps Research target estrogen-sensitive breast cancer cells in new ways, potentially creating better options for patients with treatment-resistant cancers. More information on these dual-mechanism estrogen receptor inhibitors was published by Min et...

COVID-19
Global Cancer Care

Effects of COVID-19 Infection in Children and Adolescents With Cancer: Global Analysis

In a Global Registry of COVID-19 in Childhood Cancer cohort study reported in The Lancet Oncology, Mukkada et al found that approximately one-fifth of children with cancer infected with COVID-19 worldwide had severe illness, with an associated mortality rate exceeding that reported in the general...

Multiple Myeloma

Addition of Venetoclax to Daratumumab/Dexamethasone With or Without Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma

In a phase I study reported in the Journal of Clinical Oncology, Bahlis et al found that venetoclax plus daratumumab/dexamethasone (VenDd) and VenDd with bortezomib (VenDVd) produced high rates of durable responses in patients with relapsed or refractory multiple myeloma with t(11;14) translocation ...

CNS Cancers

Cross-Sectional Survey Reveals Disparities in Care of Patients With Brain Metastases

A cross-sectional survey of patients, caregivers, and physicians on the diagnosis and treatment of brain metastases, conducted by the American Brain Tumor Association (ABTA) as part of its Metastatic Brain Tumor Initiative, revealed disparities in practice patterns and communication around...

Breast Cancer

Addition of Entinostat to Exemestane in Aromatase Inhibitor–Resistant, HR-Positive, HER2-Negative Advanced Breast Cancer

As reported in the Journal of Clinical Oncology by Roisin M. Connolly, MB, BCh, MD, and colleagues, the phase III ECOG-ACRIN Cancer Research Group E2112 trial showed no significant improvement in progression-free or overall survival with the addition of the histone deacetylase inhibitor entinostat...

Colorectal Cancer

Study Examines Link Between in Utero Events and Risk of Colorectal Cancer in Adult Offspring

Infants whose mothers were obese during pregnancy may have a heightened risk of developing colorectal cancer later in life, according to new research published by Murphy et al in the journal Gut. Obesity is already a well-established risk factor for colorectal cancer, and several studies suggest...

Bladder Cancer

Addition of ATR Inhibitor Berzosertib to Cisplatin/Gemcitabine in Metastatic Urothelial Carcinoma

In a phase II trial reported in JAMA Oncology, Sumanta K. Pal, MD, FASCO, and colleagues found that the addition of the ATR inhibitor berzosertib to cisplatin/gemcitabine provided no benefit in patients with metastatic urothelial carcinoma. The triplet did not prolong progression-free survival, and ...

Gynecologic Cancers

Inguinofemoral Radiotherapy vs Inguinofemoral Lymphadenectomy for Patients With Vulvar Cancer and Sentinel Node Metastasis

In the phase II GROINSS-V II study reported in the Journal of Clinical Oncology, Oonk et al found that inguinofemoral radiotherapy is a safe alternative to inguinofemoral lymphadenectomy in women with early-stage vulvar cancer and sentinel node micrometastasis but was associated with a higher...

Advertisement

Advertisement



Advertisement